Alkermes plc (ALKS)

About Alkermes plc

Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.

As of November 3, 2026, Alkermes plc (ALKS) stock surged to $47.25, up 5.26% (+$2.36) versus the previous close. On the day, shares have traded between $45.22 and $47.43. That puts ALKS in the upper third of its 52-week range of $27.00 to $55.67. Alkermes plc operates in the pharmaceutical preparations space and carries a market capitalization of roughly $7.61 billion, with about 706.4K shares changing hands.

Latest ALKS news

• Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to SayYahoo Finance· Nov 3, 8:30 AM ET
• Alkermes (ALKS) Surpasses Q3 Earnings and Revenue EstimatesYahoo Finance· Nov 3, 7:15 AM ET
• Alkermes: Q3 Earnings SnapshotYahoo Finance· Nov 3, 7:12 AM ETAP
• Alkermes plc Reports Third Quarter 2026 Financial ResultsYahoo Finance· Nov 3, 7:05 AM ET
• Axsome Sinks 10% Despite Q3 Revenue Beat “Surpassing a One-Billion-Dollar Annual Run Rate”tikr.com· Nov 2, 1:56 PM ET
• Alkermes (ALKS) Starts Phase 2 MDD Trial, Is The Upside Already Priced In?Yahoo Finance· Oct 31, 2:15 AM ET
• Alkermes Expands ALKS 7290 Development Program With Initiation of Phase 2 Study for the Adjunctive Treatment of Major Depressive Disorder (MDD)Yahoo Finance· Oct 30, 7:00 AM ETMDDADHD
• Alnylam Pharmaceuticals (ALNY) Q3 Earnings and Revenues Top EstimatesYahoo Finance· Oct 29, 9:30 AM ETALNY

Source: Yahoo Finance RSS · Updated November 3, 2026

Want ALKS headlines, alerts and AI research in one place? Create a free account →

• https://www.marketbeat.com/earnings/reports/2026-11-4-alkermes-plc-stock/ $ALKS Alkermes Earnings Transcript

  @EarningsInsider· Nov 3, 9:16 AM ET

• $ALKS Q3 '26 Earnings Results & Recap • Reported GAAP EPS of $0.09 down -81.63% YoY • Reported revenue of $480.13M up 21.80% YoY • Alkermes reiterated its financial expectations for 2026, as set forth in its July 28, 2026 press release; this filing does not state quant…

  @StocktwitsEarnings· Nov 3, 8:11 AM ET

• WOW! A very large, unusual order came in on $ALKS. - $1.1M+ purchased of the $55 call for Jan. 21st, 2028. Betting on about 40% upside in the next 15 months.

  @Peloswings_04· Oct 15, 5:18 PM ET

• WOW! A very large, unusual order came in on $ALKS. - $1.1M+ purchased of the $55 call for Jan. 21st, 2028. Betting on about 40% upside in the next 15 months.

  @peloswing· Oct 15, 3:31 PM ET

• $ALKS reclaimed its 200DMA and supporting trendline today! Over $1.2M in premium hit the tape for January 2028 $55 Calls! 😲 This is a beautiful set up for the long term - immediate target at ~$43!

  @theoptionsplug· Oct 15, 3:30 PM ET

Source: Stocktwits. User posts are opinions, not verified facts. See what's trending →